semaglutide cardiac Cardiovascular outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice New research reveals that semaglutide,

The problem

[Accessed 26 May 2026] Managing weight with type 2 diabetes

Takeaway for clinicians: If your CKD patient is on sulfonylureas Reconsider

Researchers using KLOW should document baseline and follow-up labs meticulously and contribute anonymized data to open-access peptide safety registries if available

Competitive athletes with type 2 diabetes should get professional guidance before going for any of the marketed semaglutide medications

8 Challenges in clinical application Considering the enumerated benefits of GLP-1RA compared to other glucose-lowering drugs including the reduction in HbA1c and weight reduction benefits alongside decreased risk for hypoglycaemia (122) it is not cost effective if used in combination with another incretin (107)